Program
Bupivacaine
Also written as “HTX-011”, “SKY0402” and “Bupivacaine HCl”.
Its studies are mostly in Pain, Postoperative · Pain · Hernia, Inguinal · Bunion · Hemorrhoids, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pacira BioSciences | 230 open or running | phase 4since Oct 24, 2011 | Jun 11, 2007 | none ahead |
| Heron Therapeutics | 171 open or running | phase 4since Oct 10, 2018 | Jun 9, 2015 | none ahead |
| Innocoll | 60 open or running | phase 3since Aug 12, 2015 | Oct 18, 2010 | none ahead |
| Bausch Health Companies | 20 open or running | phase 3since Oct 9, 2015 | Mar 30, 2010 | none ahead |
| Cristália Produtos Químicos Farmacêuticos Ltda. | 20 open or running | phase 3since Feb 23, 2011 | Feb 23, 2011 | none ahead |
| Jiangsu HengRui Medicine | 22 open or running | phase 4since Mar 13, 2024 | Mar 13, 2024 | Nov 2026phase 2 · NCT06529432 |
| Ascension Health | 10 open or running | phase 3since Nov 20, 2019 | Nov 20, 2019 | none ahead |
| liquidia-technologies-inc | 10 open or running | phase 1since Nov 22, 2016 | Nov 22, 2016 | none ahead |
| Rebel Medicine | 11 open or running | phase 2since Apr 28, 2026 | Apr 28, 2026 | none ahead |
| Tian Medical | 10 open or running | phase 4since Oct 16, 2012 | Oct 16, 2012 | none ahead |
Also a collaborator on its studies: Pfizer, premier-research-group-plc and richmond-pharmacology-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Jun 11, 2007.
- Apr 17, 2019Phase 2 study in AgnosiaHeron Therapeutics · NCT03922048
- May 9, 2019Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT03955211 · 25 enrolled · United States
- Jun 3, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03974932 · 116 enrolled · United States
- Jun 25, 2019Phase 1 study in BunionPacira BioSciences · NCT04002089 · 45 enrolled · United States
- Nov 20, 2019Ascension Health's first study: phase 3 study in AgnosiaNew to Ascension HealthAscension Health · NCT04173312 · 120 enrolled · United States
- Aug 4, 2020Phase 3 study in BunionPacira BioSciences · NCT04518462 · 121 enrolled · United States
- Mar 1, 20212 phase 3 studies in Pain, PostoperativeInnocoll · NCT04785638, NCT04785625
- May 27, 2021Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT04911062 · 32 enrolled · United States
- Oct 1, 2021Phase 4 study in AgnosiaHeron Therapeutics · NCT05109312 · 90 enrolled · United States
- Oct 25, 20232 phase 4 studies in Pain, PostoperativeHeron Therapeutics · NCT06109428, NCT06109415
- Mar 13, 2024Jiangsu HengRui Medicine's first study: phase 4 study in Local Analgesia Via InfiltrationNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06344091 · 232 planned · China
- Jul 26, 2024Phase 2 study in Local Analgesia Via Nerve BlockJiangsu HengRui Medicine · NCT06529432 · 96 planned · China
- Apr 28, 2026Rebel Medicine's first study: phase 2 study in Hallux ValgusNew to Rebel MedicineRebel Medicine · NCT07574385 · 60 planned · United States
- Sep 28, 2026Primary completion moved from 2026-09-28 to 2027-05Date moved laterphase 4 · +8 months · NCT06344091
Ahead
- Nov 2026Primary completion: phase 2 study in Local Analgesia Via Nerve BlockJiangsu HengRui Medicine · NCT06529432
- May 2027Primary completion: phase 4 study in Local Analgesia Via InfiltrationJiangsu HengRui Medicine · NCT06344091
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 56 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07574385Hallux Valgus · United States | 2 | Recruiting | Rebel Medicine | Aug 2026 | 60 |
| NCT06529432Local Analgesia Via Nerve Block · China | 2 | Recruiting | Jiangsu HengRui Medicine | Nov 2026 | 96 |
| NCT06344091Local Analgesia Via Infiltration · China | 4 | Recruiting | Jiangsu HengRui Medicine | May 2027 | 232 |
| NCT06109428Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Mar 29, 2022 | 37 |
| NCT06109415Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Jul 18, 2022 | 30 |
| NCT05109312Agnosia · United States | 4 | Active, not recruiting | Heron Therapeutics | Jun 2024 | 90 |
| NCT04911062Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Jul 29, 2022 | 32 |
| NCT04785638Pain, Postoperative · United States | 3 | Completed | Innocoll | Jan 10, 2023 | 100 |
| NCT04785625Pain, Postoperative · United States | 3 | Completed | Innocoll | Oct 27, 2021 | 366 |
| NCT04518462Bunion · United States | 3 | Completed | Pacira BioSciences | Apr 5, 2021 | 121 |
| NCT04173312Agnosia · United States | 3 | UNKNOWN | Ascension Health | Jan 2023 | 120 |
| NCT04002089Bunion · United States | 1 | Completed | Pacira BioSciences | Dec 2, 2019 | 45 |
| NCT03974932Agnosia · United States | 3 | Completed | Heron Therapeutics | Dec 7, 2020 | 116 |
| NCT03955211Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Dec 3, 2021 | 25 |
| NCT03922048Agnosia | 2 | Withdrawn | Heron Therapeutics | Nov 2025 | 0 |
| NCT03907176Agnosia · United States | 3 | Completed | Heron Therapeutics | Oct 25, 2021 | 209 |
| NCT03718039Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Jan 31, 2019 | 78 |
| NCT03705065Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Oct 8, 2018 | 30 |
| NCT03695367Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Nov 20, 2018 | 63 |
| NCT03295721Pain, Postoperative · United States | 3 | Completed | Heron Therapeutics | Jan 8, 2018 | 412 |
| NCT03262688Hernia, Inguinal · United States | 3 | UNKNOWN | Innocoll | Jan 31, 2024 | 159 |
| NCT03237481Pain, Postoperative · United States, Belgium | 3 | Completed | Heron Therapeutics | Dec 22, 2017 | 418 |
| NCT03015532Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Apr 20, 2018 | 285 |
| NCT03011333Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Feb 1, 2018 | 243 |
| NCT02982889Acute Pain · Denmark | 1 | Completed | liquidia-technologies-inc | Mar 23, 2017 | 29 |
| NCT02713490Pain · United States | 4 | Completed | Pacira BioSciences | Feb 8, 2017 | 140 |
| NCT02574520Pain, Postoperative · United States | 3 | Completed | Bausch Health Companies | Jun 2017 | 399 |
| NCT02525133Pain, Postoperative · United States | 3 | Completed | Innocoll | Apr 22, 2016 | 319 |
| NCT02523599Pain, Postoperative · United States | 3 | Completed | Innocoll | Apr 2016 | 305 |
| NCT02517905Toothache · United States | 3 | Completed | Pacira BioSciences | Jan 2016 | 166 |
| NCT02504580Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Mar 2017 | 463 |
| NCT02471898Agnosia · United States | 2 | Completed | Heron Therapeutics | Sep 2015 | 71 |
| NCT02284386Pain · United States | 4 | Completed | Pacira BioSciences | Mar 2015 | 15 |
| NCT02255500Pain · United States | 4 | Completed | Pacira BioSciences | Mar 2015 | 23 |
| NCT02142829Obesity · United States | 4 | Completed | Pacira BioSciences | Mar 2013 | 101 |
| NCT01709708Migraine Disorders · United States | 4 | Completed | Tian Medical | Feb 2014 | 41 |
| NCT01507220Intestinal Obstruction · United States | 4 | Terminated | Pacira BioSciences | Jul 2012 | 2 |
| NCT01308047Fracture of Lower Limb · Brazil | 3 | Withdrawn | Cristália Produtos Químicos Farmacêuticos Ltda. | 0 | |
| NCT01303107Cesarean Delivery · Brazil | 3 | Withdrawn | Cristália Produtos Químicos Farmacêuticos Ltda. | 0 | |
| NCT01224145Hernia · United States | 2 | Completed | Innocoll | Jun 20, 2011 | 10 |
| NCT01206608Pain, Postoperative · United States | 2 | Completed | Pacira BioSciences | Aug 2008 | 40 |
| NCT01206595Pain, Postoperative | 2 | Completed | Pacira BioSciences | Mar 2006 | 58 |
| NCT01203644Hernia, Inguinal | 2 | Completed | Pacira BioSciences | Jan 2006 | 76 |
| NCT01096966Chronic Low Back Pain · United States | 2 | Completed | Bausch Health Companies | Feb 2011 | 263 |
| NCT00890721Hemorrhoids · Poland | 3 | Completed | Pacira BioSciences | Nov 2009 | 189 |
| NCT00890682Bunion · United States | 3 | Completed | Pacira BioSciences | Nov 2009 | 193 |
| NCT00813111Pain · United States | 3 | Terminated | Pacira BioSciences | Feb 2009 | 136 |
| NCT00812305Pain · Poland | 1 | Completed | Pacira BioSciences | Aug 2009 | 16 |
| NCT00807209Pain, Postoperative · United States | 2 | Terminated | Pacira BioSciences | Feb 2009 | 3 |
| NCT00806806Agnosia · United States | 1 | Completed | Pacira BioSciences | Feb 2009 | 128 |
| NCT00745290Pain, Postoperative · United States | 3 | Completed | Pacira BioSciences | Jan 2009 | 245 |
| NCT00744848Hemorrhoids · United States | 3 | Completed | Pacira BioSciences | Feb 2009 | 204 |
| NCT00529126Pain, Postoperative · United States, Georgia | 2 | Completed | Pacira BioSciences | Dec 2007 | 100 |
| NCT00485693Pain, Postoperative · United States, Czechia | 2 | Completed | Pacira BioSciences | Aug 2009 | 138 |
| NCT00485667Pain, Postoperative · United Kingdom | 1 | Completed | Pacira BioSciences | Aug 2007 | 48 |
| NCT00485433Pain, Postoperative · United States | 2 | Completed | Pacira BioSciences | Dec 2007 | 98 |
How it is read
Names in the registry
- “HTX-011”, 20 entries
- “SKY0402”, 12 entries
- “Bupivacaine HCl”, 7 entries
- “Bupivacaine”, 5 entries
- “Bupivacaine Liposome Injection”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 27 studies
- Pain, 5 studies
- Hernia, Inguinal, 4 studies
- Bunion, 3 studies
- Hemorrhoids, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.